Publicacións en colaboración con investigadores/as de Hospital de Fuenlabrada (13)

2024

  1. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

    Neuromuscular Disorders, Vol. 34, pp. 1-8

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

2021

  1. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  2. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  3. Non-inflammatory causes of emergency consultation in patients with multiple sclerosis

    Neurologia, Vol. 36, Núm. 6, pp. 403-411

  4. Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: Case report and literature review

    Multiple Sclerosis and Related Disorders, Vol. 49

2020

  1. Ethyl alcohol threshold test: a fast, reliable and affordable olfactory Assessment tool for COVID-19 patients

    European Archives of Oto-Rhino-Laryngology, Vol. 277, Núm. 10, pp. 2783-2792

2019

  1. Self-reported periodontitis and migraine: results from a multicenter, cross-sectional survey in Spain

    Odontology, Vol. 107, Núm. 4, pp. 530-535

2018

  1. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study

    European Journal of Neurology, Vol. 25, Núm. 2, pp. 411-416

2017

  1. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation

    Brain and Behavior, Vol. 7, Núm. 4

2014

  1. Long-term effectiveness of glatiramer acetate in clinical practice conditions

    Journal of Clinical Neuroscience, Vol. 21, Núm. 12, pp. 2212-2218

2012

  1. Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study

    Movement Disorders, Vol. 27, Núm. 2, pp. 211-218